Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (SOLO-1)
Source: View publication →
In patients with newly diagnosed advanced ovarian cancer and a BRCA mutation, first-line maintenance therapy with olaparib significantly prolonged progression-free survival by 70% compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
SOLO-1 fundamentally revolutionized the standard of care for newly diagnosed advanced ovarian cancer. The trial demonstrated an unprecedented magnitude of benefit (PFS hazard ratio of 0.30), establishing olaparib as an essential first-line maintenance therapy for patients with BRCA mutations. This profound clinical efficacy shifted clinical practice guidelines to mandate upfront somatic and germline BRCA testing for all newly diagnosed advanced ovarian cancer patients, ensuring they can be evaluated for early, highly efficacious PARP inhibition.
Historical Context
Historically, most women with advanced ovarian cancer experience disease relapse within 3 years despite robust initial responses to cytoreductive surgery and platinum-based chemotherapy. Prior to the SOLO-1 trial, poly(ADP-ribose) polymerase (PARP) inhibitors had demonstrated significant efficacy and were approved solely for the treatment of recurrent disease, specifically as maintenance therapy for platinum-sensitive relapsed ovarian cancer (such as in Study 19 and SOLO-2). SOLO-1 was a landmark phase 3 trial that moved PARP inhibition into the first-line maintenance setting, aiming to capitalize on minimal residual disease burden after primary therapy to deeply extend remission and potentially increase the fraction of cured patients.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of synthetic lethality explain the profound efficacy of olaparib specifically in ovarian cancer patients who harbor a BRCA1 or BRCA2 mutation?
Key Response
Olaparib is a PARP inhibitor. PARP enzymes repair single-strand DNA breaks. If PARP is inhibited, single-strand breaks degenerate into double-strand breaks during cellular replication. Normal cells repair these efficiently via homologous recombination (HR). However, BRCA-mutated cells have defective HR, forcing them to use error-prone pathways like non-homologous end joining. This leads to massive genomic instability and subsequent cell death, perfectly illustrating the concept of synthetic lethality.
Based on the SOLO-1 trial results, which specific subset of newly diagnosed ovarian cancer patients should undergo germline and somatic testing, and at what point in their treatment timeline should this testing occur to optimize maintenance therapy decisions?
Key Response
All patients with newly diagnosed advanced epithelial ovarian cancer should undergo BRCA testing (both germline and somatic) at the time of diagnosis. Knowing the BRCA status early is critical because patients with a BRCA mutation who achieve a complete or partial clinical response to front-line platinum-based chemotherapy are prime candidates for olaparib maintenance, which reduces the risk of disease progression or death by 70% according to SOLO-1.
The SOLO-1 trial mandated a 2-year treatment cap for olaparib in patients with a complete response, unlike the continuous dosing until progression used in the recurrent setting. What is the clinical and biological rationale behind this fixed-duration maintenance?
Key Response
In the upfront setting, a subset of advanced ovarian cancer patients may be cured with surgery and platinum chemotherapy alone. Capping treatment at 2 years limits cumulative toxicity and the rare but fatal risk of secondary myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) in potentially cured patients, while still providing a durable, sustained progression-free survival benefit that extends well beyond the 2-year cessation mark.
Given the unprecedented hazard ratio of 0.30 for progression-free survival in SOLO-1, how do you adjust your clinical counseling for a newly diagnosed BRCA-mutated patient regarding the paradigm shift from viewing advanced ovarian cancer as an inevitably relapsing disease?
Key Response
Historically, 70-80% of advanced ovarian cancers relapse after front-line therapy. The SOLO-1 data demonstrated that at 5 years, nearly half of the olaparib group was progression-free. Counseling must shift to emphasize the high probability of long-term durable remission, framing front-line maintenance olaparib not just as a delay to recurrence, but as a potential bridge to a functional cure, while responsibly managing expectations and monitoring for late-onset toxicities.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The SOLO-1 trial utilized investigator-assessed progression-free survival as its primary endpoint rather than blinded independent central review (BICR) for the primary analysis. How might assessment bias affect a progression-free survival endpoint, and why is the reported magnitude of benefit robust enough to withstand such potential biases?
Key Response
Investigator-assessed PFS can introduce bias, especially if specific toxicity profiles (like anemia or fatigue) unblind the investigator to the treatment assignment. However, with a massive effect size (HR=0.30) and a highly significant p-value, the potential inflation of the effect due to unblinding is vastly overshadowed by the true biological signal. A secondary sensitivity analysis using BICR in SOLO-1 confirmed the investigator-assessed results, validating the methodological choice.
While the progression-free survival benefit in SOLO-1 was staggering, the overall survival (OS) data was immature at the time of initial publication. As an editor, how do you weigh the decision to publish practice-changing data based on a surrogate endpoint (PFS) in a disease state where post-progression crossover therapies heavily confound OS?
Key Response
PFS is a valid, clinically meaningful endpoint in front-line ovarian cancer because it reflects the period a patient is entirely free of disease and subsequent chemotherapy toxicity. An editor must evaluate if the magnitude of the PFS benefit justifies immediate dissemination. Waiting for mature OS data would unethically delay patient access to a highly efficacious drug, especially knowing that crossover to PARP inhibitors in subsequent lines will likely dilute the final statistical OS signal.
How did the SOLO-1 efficacy data prompt guideline committees (such as ASCO and NCCN) to upgrade the recommendation for front-line maintenance therapy from a conditional option to a strong Category 1 recommendation for PARP inhibitors in BRCA-mutated advanced ovarian cancer?
Key Response
Prior to SOLO-1, maintenance therapy in the front-line setting was heavily debated and largely limited to bevacizumab with modest PFS gains. The unprecedented PFS benefit (median PFS not reached vs 13.8 months, HR 0.30) provided undeniable Level 1 evidence. This fundamentally changed NCCN and ASCO guidelines to strongly recommend (Category 1) olaparib maintenance for 2 years in BRCA-mutated patients responding to primary platinum-based chemotherapy, establishing a new, definitive global standard of care.
Clinical Landscape
Noteworthy Related Trials
SOLO-2 Trial
Tested
Olaparib
Population
Platinum-sensitive relapsed ovarian cancer with a BRCA mutation
Comparator
Placebo
Endpoint
Progression-free survival (PFS)
PRIMA Trial
Tested
Niraparib
Population
Newly diagnosed advanced ovarian cancer after platinum-based chemotherapy
Comparator
Placebo
Endpoint
Progression-free survival (PFS)
PAOLA-1 Trial
Tested
Olaparib plus Bevacizumab
Population
Advanced ovarian cancer responding to first-line platinum-based chemotherapy plus bevacizumab
Comparator
Placebo plus Bevacizumab
Endpoint
Progression-free survival (PFS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis